ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1930

Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis

Shu Cao1, Caroline Bresnan2, Si Li3, Yichen Wang3 and Yih Chang Lin1, 1University of South Florida, Morsani College of Medicine, Tampa, FL, 2University of South Florida, Morsani College of Medicine, Tampa, 3The Wright Center for Graduate Medical Education, Scranton

Meeting: ACR Convergence 2020

Keywords: giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with high potential for morbidity leading to frequent hospitalizations and significant economic burden to the healthcare system. The goal of this study is to use Nationwide Readmissions Database (NRD) to determine the 30-day readmission rate of patients that were initially admitted for active GCA, to identify the reasons and predictors for readmission.

Methods: This is a retrospective cohort study using the NRD from 2016 and 2017. The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) was used to identify diagnoses. The primary outcome was rate of all-cause readmission within 30 days of discharge for all patients with principle diagnoses of GCA on index admission. Secondary outcomes were principle diagnoses for readmission, predictive factors and resource use. We compared baseline demographics and calculated all-cause 30-day readmission rates in patients who survived their index hospitalization. Proportions were compared using the Fisher exact test, and continuous variables were compared using the Student t-test. Logistic regressions were used for binary outcomes and linear regressions were used for continuous outcomes. Multivariate logistic regression was conducted using Stata, version 16.0 to determine the predictors for readmission. All p-values were two-sided, with 0.05 as the threshold for statistical significance.

Results: There were 4,841 patients admitted for active GCA flares in the NRD from 2016 to 2017, of which 68.7% were female. The mean age was 72.4±11.9 years. The all cause 30-day readmission rate was 13.1%. The 30-day mortality rate was 0.7%. The five most common reasons for readmissions were GCA, acute kidney failure, sepsis, paroxysmal atrial fibrillation, type 2 diabetes mellitus with hyperglycemia. The adjusted odds ratios (aOR) and p-values were calculated and independent predictors of GCA readmission were identified: Coexisting heart failure (aOR 1.63, 95% CI 1.14- 2.34, p= 0.007) and higher Charlson comorbidity score (aOR 1.16, 95% CI 1.08- 1.23, p< 0.001). Discharge from teaching hospitals was associated with lower odds of being readmitted (aOR 0.72, 95% CI 0.55- 0.95, p=0.019). The total hospital days associated with readmission were 3,894 days, with a total healthcare cost of $8.54 million.

Conclusion: This study showed 13.1% of the patients who were initially admitted for active GCA were readmitted within 30 days, creating a significant economic burden. Patients with coexisting heart failure and higher Charlson comorbidity core were significantly more likely to be readmitted.

We should be more cognizant of the poor outcomes and high disease burden of active GCA and its treatment complications which may lead to unnecessary readmission including infection, hyperglycemia and renal failure. More study on preventing GCA readmission is warranted.


Disclosure: S. Cao, None; C. Bresnan, None; S. Li, None; Y. Wang, None; Y. Lin, None.

To cite this abstract in AMA style:

Cao S, Bresnan C, Li S, Wang Y, Lin Y. Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/thirty-day-readmission-rate-in-patients-who-were-initially-admitted-for-active-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/thirty-day-readmission-rate-in-patients-who-were-initially-admitted-for-active-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology